Ranibizumab

Generic Name
Ranibizumab
Brand Names
Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
Drug Type
Biotech
Chemical Formula
-
CAS Number
347396-82-1
Unique Ingredient Identifier
ZL1R02VT79
Background

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular (wet) age-related macular degeneration. The development of ranibizumab first began after bevacizumab, another anti-VEGF anticancer drug, was discovered to inhibit neovascularization and used in the off-label treatment of neovascular age-related macular degeneration for intravenous injection. In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use.

Ranibizumab was initially approved by the FDA in 2006 and by the European Commission (EC) in 2007. It is marketed under the brand names LUCENTIS and SUSVIMO. BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada. In August 2022, other biosimilars CIMERLI and RAIVISIO were approved by the FDA and EC, respectively.

Indication

Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.

Ranibizumab injection for for intravitreal use via ocular implant is used to treat Neovascular (wet) Age-related Macular Degeneration (AMD) in patients who have responded to at least two intravitreal injections of a VEGF inhibitor.

Associated Conditions
Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
Associated Therapies
-

ERG/EOG Study in AMD Patients Treated With Ranibizumab

First Posted Date
2008-11-14
Last Posted Date
2015-05-08
Lead Sponsor
Retina Center, Minnesota
Target Recruit Count
10
Registration Number
NCT00791427
Locations
🇺🇸

The Retina Center, Minneapolis, Minnesota, United States

Ranibizumab for the Inhibition of Neovascularization in Pterygia

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-10-08
Last Posted Date
2017-07-11
Lead Sponsor
University of Miami
Target Recruit Count
10
Registration Number
NCT00768963
Locations
🇺🇸

Bascom Palmer Eye Institute, Miami, Florida, United States

Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-10-08
Last Posted Date
2017-07-11
Lead Sponsor
University of Miami
Target Recruit Count
5
Registration Number
NCT00769145
Locations
🇺🇸

Bascom Palmer Eye Institute, Miami, Florida, United States

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-10-03
Last Posted Date
2016-12-02
Lead Sponsor
Massachusetts Eye and Ear Infirmary
Target Recruit Count
40
Registration Number
NCT00765921
Locations
🇺🇸

Massachusetts Eye & Ear Infirmary, Boston, Massachusetts, United States

Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-09-10
Last Posted Date
2012-04-26
Lead Sponsor
The New York Eye Cancer Center
Target Recruit Count
10
Registration Number
NCT00750399
Locations
🇺🇸

The New York Eye Cancer Center, New York, New York, United States

Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-09-09
Last Posted Date
2012-10-05
Lead Sponsor
Clement K. Chan
Target Recruit Count
40
Registration Number
NCT00749021
Locations
🇺🇸

Black Hills Regional Eye Institute, Rapid City, South Dakota, United States

🇺🇸

Jules Stein Eye Institute, Los Angeles, California, United States

🇺🇸

Southern California Desert Retina Consultants, Palm Desert, California, United States

VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)

First Posted Date
2008-08-04
Last Posted Date
2015-05-28
Lead Sponsor
University of Zurich
Target Recruit Count
54
Registration Number
NCT00727753
Locations
🇨🇭

University Hospital Zurich, Division of Cardiology, Zurich, ZH, Switzerland

Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)

Not Applicable
Withdrawn
Conditions
Interventions
First Posted Date
2008-08-01
Last Posted Date
2012-05-10
Lead Sponsor
Lahey Clinic
Registration Number
NCT00726973

Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration

First Posted Date
2008-07-04
Last Posted Date
2010-06-09
Lead Sponsor
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Target Recruit Count
320
Registration Number
NCT00710229
Locations
🇦🇹

Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery, Vienna, Austria

A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study

First Posted Date
2008-06-02
Last Posted Date
2013-04-01
Lead Sponsor
Novartis
Target Recruit Count
345
Registration Number
NCT00687804
Locations
🇨🇭

Novartis Investigational Site, Zurich, Switzerland

🇬🇧

Novartis Investigative Site, Upton, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath